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reported.
Study design
The study was a retrospective case-control study that was conducted in a single centre. Three study periods were compared. More specifically, the 12 months before WBC reduction (period 1, 1991) , the 24 months during WBC reduction (period 2, 1992 -1993) , and the 12 months following WBC reduction (period 3, 1994) . The patients were followed up for the duration of their hospital stay. The retrospective nature of the study means that there was no loss to follow-up. There was no blinding in this study.
Analysis of effectiveness
The nature of the study means that the analysis of the clinical effectiveness data was conducted for treatment completers only. The incidence of postoperative infections and the length of hospital stay were used as the measures of effectiveness. The patients who did not receive a blood transfusion were more likely to be male and to be aged younger than those who received a transfusion. However, the analysis of the data considered whether there was a difference in trends over time between the two groups, and the only statistically significant difference in age and gender between the patient groups was that the mean age of the patients who received a transfusion increased slightly from 70 years in the first time period to 72 years in the final period.
Effectiveness results
Among patients who received a transfusion, the incidence of postoperative infection was 11% prior to the use of WBCreduced blood, 13% during the use of WBC-reduced blood, and 7% after the discontinuation of WBC-reduced blood, (p=0.04).
Among patients who did not have a transfusion, the incidence of postoperative infection was 7% prior to the use of WBC-reduced blood, 7% during the use of WBC-reduced blood, and 2% after the discontinuation of WBC-reduced blood, (p=0.06).
The mean length of stay decreased significantly over time for patients who received transfusion, changing from 15.91 days before WBC reduction, to 14.12 days during WBC reduction and 12.14 days following WBC reduction, (p=0.001).
A similar trend was observed in the patients who did not receive transfusion. The mean length of stay changed from 11.01 days before WBC reduction, to 9.95 days during WBC reduction and to 8.27 days following WBC reduction, (p=0.001).
Clinical conclusions
The authors concluded that the use of WBC-reduced blood did not alter the length of hospital stay and the incidence of postoperative infection.
Measure of benefits used in the economic analysis
No summary measure of benefit was used in the economic analysis. In effect, a cost-consequences analysis was carried out.
Direct costs
The estimation of costs was derived from the patient sample. The authors only stated that the cost of hospital care was taken from the patients' hospital records. The cost components were not reported separately. The prices used related to the year in which the patient was treated. Consequently, no single price year was used. The costs were not discounted. reduce the length of hospital stay and cost of care for all patients. Thus, a randomised controlled trial would have provided a more robust study design. The study groups were not comparable at baseline. Hence, confounding factors may be high. The study sample was likely to have been representative of the patient population, although this was not discussed. A statistical analysis was performed to investigate whether the results were statistically significant. However, power calculations were not carried out, thus the sample size might have been too small to detect significant differences in outcomes between the groups.
Validity of estimate of measure of benefit
The authors did not derive a summary measure of health benefit. The analysis was, in effect, a cost-consequences analysis.
Validity of estimate of costs
The authors did not report the economic perspective of the study. However, it seems that the perspective adopted was that of the hospital. The total hospital costs were estimated for each group, although the cost components these costs included were not reported. The resource use data and the unit costs were not reported separately. No single price year was used. The cost estimates were derived from a single centre and were specific to the study setting. These facts limit the reproducibility of the study findings. The fact that the costs were calculated and analysed using prices at the time of treating, and no reflation exercise was undertaken, means that the internal validity of the cost results is limited. Statistical tests were performed when the cost estimates were compared. However, sensitivity analyses on the costs were not performed. This means that uncertainty surrounding the study results has not been assessed, thus the generalisability of the study is reduced. Discounting was appropriately not undertaken since the cost per case was incurred during less than 2 years.
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